BRPI0720211A2 - Derivado de indanona, composição, e, uso de uma composição - Google Patents

Derivado de indanona, composição, e, uso de uma composição

Info

Publication number
BRPI0720211A2
BRPI0720211A2 BRPI0720211-3A2A BRPI0720211A BRPI0720211A2 BR PI0720211 A2 BRPI0720211 A2 BR PI0720211A2 BR PI0720211 A BRPI0720211 A BR PI0720211A BR PI0720211 A2 BRPI0720211 A2 BR PI0720211A2
Authority
BR
Brazil
Prior art keywords
composition
indanone derivative
indanone
derivative
Prior art date
Application number
BRPI0720211-3A2A
Other languages
English (en)
Inventor
Laxminarayan Bhat
Prabhu Prasad Mohapatra
Original Assignee
Reviva Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Reviva Pharmaceuticals Inc filed Critical Reviva Pharmaceuticals Inc
Publication of BRPI0720211A2 publication Critical patent/BRPI0720211A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
    • C07D211/22—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Hydrogenated Pyridines (AREA)
BRPI0720211-3A2A 2006-12-11 2007-12-11 Derivado de indanona, composição, e, uso de uma composição BRPI0720211A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US86949906P 2006-12-11 2006-12-11
PCT/US2007/025392 WO2008073452A1 (en) 2006-12-11 2007-12-11 Compositions, synthesis, and methods of using indanone based cholinesterase inhibitors

Publications (1)

Publication Number Publication Date
BRPI0720211A2 true BRPI0720211A2 (pt) 2013-12-24

Family

ID=39512052

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0720211-3A2A BRPI0720211A2 (pt) 2006-12-11 2007-12-11 Derivado de indanona, composição, e, uso de uma composição

Country Status (13)

Country Link
US (2) US8247563B2 (pt)
EP (1) EP2114166A4 (pt)
JP (1) JP2010512328A (pt)
CN (1) CN101626688A (pt)
AU (1) AU2007333586A1 (pt)
BR (1) BRPI0720211A2 (pt)
CA (1) CA2672212A1 (pt)
IL (1) IL198921A0 (pt)
MX (1) MX2009005795A (pt)
NZ (1) NZ578187A (pt)
RU (1) RU2478619C2 (pt)
WO (1) WO2008073452A1 (pt)
ZA (1) ZA200904211B (pt)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007108011A2 (en) * 2006-03-20 2007-09-27 Ind-Swift Laboratories Limited Process for the preparation of highly pure donepezil
MY158047A (en) * 2008-10-02 2016-08-30 Korea Res Inst Chem Tech Uracil compounds and a herebicide comprising the same
AU2011215870B2 (en) 2010-02-09 2016-01-28 The Johns Hopkins University Methods and compositions for improving cognitive function
ES2365316B1 (es) 2010-03-18 2012-09-06 Consejo Superior De Investigaciones Científicas (Csic) Nuevos derivados de propargilamina con capacidad neuroprotectora para el tratamiento de las enfermedades de alzheimer y parkinson.
WO2011153359A1 (en) 2010-06-04 2011-12-08 Albany Molecular Research, Inc. Glycine transporter-1 inhibitors, methods of making them, and uses thereof
CN103524515B (zh) * 2012-07-03 2016-07-06 浙江海正药业股份有限公司 具有乙酰胆碱酯酶抑制活性的苯并间二氧杂环戊烯衍生物及其制备方法和用途
US9249098B2 (en) * 2012-07-10 2016-02-02 Xueheng Cheng Derivatives of donepezil
CN103787954B (zh) * 2012-10-26 2016-01-20 中国科学院上海药物研究所 一类氟取代的环状胺类化合物及其制备方法、药物组合物和用途
US20140206667A1 (en) 2012-11-14 2014-07-24 Michela Gallagher Methods and compositions for treating schizophrenia
JP6433482B2 (ja) 2013-03-15 2018-12-05 エージンバイオ， インコーポレイテッド 認知機能を改善するための方法および組成物
WO2014144663A1 (en) 2013-03-15 2014-09-18 The Johns Hopkins University Methods and compositions for improving cognitive function
BR102013030928A2 (pt) * 2013-11-29 2015-09-22 Cristália Produtos Químicos Farmacêuticos Ltda processo para a preparação de cloridrato de donepezila formas i e iii; e de um composto intermediário do mesmo
TW201625601A (zh) 2014-07-02 2016-07-16 諾華公司 噻吩－２－基－吡啶－２－基－１ｈ－吡唑－４－羧酸衍生物及其作為可溶性鳥苷酸環化酶活化劑之用途
TW201625584A (zh) * 2014-07-02 2016-07-16 諾華公司 茚滿及吲哚啉衍生物及其作為可溶性鳥苷酸環化酶活化劑之用途
TW201625586A (zh) 2014-07-02 2016-07-16 諾華公司 環己烯－１－基－吡啶－２－基－１ｈ－吡唑－４－羧酸衍生物及其作為可溶性鳥苷酸環化酶活化劑之用途
WO2016191288A1 (en) 2015-05-22 2016-12-01 Agenebio, Inc. Extended release pharmaceutical compositions of levetiracetam
CN105859732B (zh) * 2016-04-11 2018-04-06 浙江海正药业股份有限公司 制备ad‑35的工艺
JP6899120B2 (ja) * 2016-10-12 2021-07-07 株式会社ナノエッグ アセチルコリンエステラーゼ（ＡＣｈＥ）阻害剤
US11082516B2 (en) 2017-12-01 2021-08-03 Hewlett-Packard Development Company, L.P. Computer devices to establish network connections
EP3946299A4 (en) * 2019-03-29 2022-11-23 Taiwanj Pharmaceuticals Co., Ltd. BENZENE DERIVATIVES EXTENDED WITH PERIPHERAL ALKYL AND ALKENYL CHAIN EXTENDED AND PHARMACEUTICAL COMPOSITIONS THEREOF

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3845770A (en) * 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) * 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
FR2484415A1 (fr) 1980-06-13 1981-12-18 Pharmindustrie Nouveaux derives de l'indene, procedes pour leur preparation, et leur utilisation comme medicaments
US4668687A (en) * 1984-07-23 1987-05-26 Bristol-Myers Company Psychogeriatric 1-(2-pyrimidinyl)piperazinyl derivatives of 1-pyrrolidin-2-ones
FI95572C (fi) * 1987-06-22 1996-02-26 Eisai Co Ltd Menetelmä lääkeaineena käyttökelpoisen piperidiinijohdannaisten tai sen farmaseuttisen suolan valmistamiseksi
DE3815221C2 (de) * 1988-05-04 1995-06-29 Gradinger F Hermes Pharma Verwendung einer Retinol- und/oder Retinsäureester enthaltenden pharmazeutischen Zubereitung zur Inhalation zur Einwirkung auf die Schleimhäute des Tracheo-Bronchialtraktes einschließlich der Lungenalveolen
US5698155A (en) * 1991-05-31 1997-12-16 Gs Technologies, Inc. Method for the manufacture of pharmaceutical cellulose capsules
EP0535496A1 (en) * 1991-09-25 1993-04-07 Hoechst-Roussel Pharmaceuticals Incorporated (1-Indanon-2yl)methylpiperidines, intermediates and a process for their preparation and their use as medicaments
US5272158A (en) * 1991-10-29 1993-12-21 Merck & Co., Inc. Fibrinogen receptor antagonists
DE4439822A1 (de) * 1994-11-08 1996-08-29 Bayer Ag Verfahren zur Herstellung von Benzyl-piperidylmethyl-indanonen
EP0728737B1 (en) * 1995-02-24 1998-10-28 Kao Corporation Quaternary ammonium salt, method for production thereof, and its use within a softener composition
CZ180898A3 (cs) 1995-12-15 1999-05-12 Pfizer Inc. Způsob a meziprodukty pro výrobu 1-benzyl-4-((5,6-dimethoxy-1-indanon)-2-yl)methylpiperidinu
SK285312B6 (sk) 1996-06-07 2006-10-05 Eisai Co., Ltd. Polymorf (III) donepezil hydrochloridu, spôsob jeho výroby a terapeutický prostriedok s jeho obsahom
CA2310250A1 (en) * 1997-11-14 1999-05-27 August Masaru Watanabe Treatment for alzheimer's disease
ATE292116T1 (de) * 1998-01-16 2005-04-15 Eisai Co Ltd Verfahren zur herstellung von donepezilderivaten
IL125809A (en) 1998-08-17 2005-08-31 Finetech Lab Ltd Process and intermediates for production of donepezil and related compounds
US6677330B1 (en) * 1999-03-03 2004-01-13 Eisai Co., Ltd. Fluorides of 4-substituted piperidine derivatives
WO2001016105A1 (en) 1999-09-01 2001-03-08 Eisai Co., Ltd. 4-substituted piperidine derivatives
WO2001032115A1 (en) * 1999-11-04 2001-05-10 Xel Herbaceuticals Transdermal administration of huperzine
US7166617B2 (en) 2000-02-29 2007-01-23 Mitsubishi Pharma Corporation Cyclic amide derivatives
US20050107432A1 (en) 2002-01-22 2005-05-19 Yoichi Iimura Sigma receptor binder containing indanone derivative
CA2478502A1 (en) * 2002-04-01 2003-10-09 Cadila Healthcare Limited Novel antiinfective compounds, process for their preparation and pharmaceutical compositions containing them
US7148354B2 (en) * 2002-07-24 2006-12-12 Dr. Reddy's Laboratories Limited Process for preparation of donepezil
US6953856B2 (en) * 2003-02-12 2005-10-11 Usv, Limited Process for the preparation of 1-benzyl-4-(5,6-dimethoxy-1-indanon)-2-yl) methyl piperidine hydrochloride (Donepezil HCI)
US7446203B2 (en) * 2003-07-01 2008-11-04 Hetero Drugs Limited Preparation of intermediates for acetycholinesterase inhibitors
TW200524865A (en) * 2003-10-08 2005-08-01 Nicholas Piramal India Ltd Fibrinogen receptor antagonists and their use
WO2005076749A2 (en) 2004-02-11 2005-08-25 Jubilant Organosys Limited A novel process for the preparation of 1-benzyl-4-[(5,6-dimethoxy-1-indanon-2-yl)methyl]piperidine
JP2008280248A (ja) 2005-11-02 2008-11-20 Eisai R & D Management Co Ltd アルツハイマー型痴呆症治療薬塩酸ドネペジルのプロドラッグ
NZ569532A (en) 2006-01-04 2010-11-26 Cipla Ltd Process and intermediate for preparation of donepezil

Also Published As

Publication number Publication date
RU2478619C2 (ru) 2013-04-10
ZA200904211B (en) 2010-03-31
WO2008073452A1 (en) 2008-06-19
US20120252842A1 (en) 2012-10-04
EP2114166A1 (en) 2009-11-11
US8580822B2 (en) 2013-11-12
JP2010512328A (ja) 2010-04-22
CA2672212A1 (en) 2008-06-19
IL198921A0 (en) 2010-02-17
MX2009005795A (es) 2009-06-08
RU2009126589A (ru) 2011-01-20
US20080153878A1 (en) 2008-06-26
AU2007333586A1 (en) 2008-06-19
WO2008073452A8 (en) 2009-01-22
EP2114166A4 (en) 2011-05-25
US8247563B2 (en) 2012-08-21
CN101626688A (zh) 2010-01-13
NZ578187A (en) 2012-05-25

Similar Documents

Publication Publication Date Title
BRPI0720211A2 (pt) Derivado de indanona, composição, e, uso de uma composição
BRPI0813770A2 (pt) Composição, e, uso de uma composição
BRPI0908792A2 (pt) Composição, e, uso de uma combinação
BRPI0821165A2 (pt) Uso de uma composição
BRPI0810696A2 (pt) Composto, composição farmacêutica, e, uso de um composto
BRPI0609802A2 (pt) composto, composição farmacêutica e uso de um composto
DK1884242T3 (da) Farmaceutisk sammensætning omfattende lurasidon
BRPI0813627A2 (pt) Peptídio antimicrobiano, composições e métodos de uso
BRPI0914793A2 (pt) Composição, e, uso de uma composição
BRPI0919942A2 (pt) Composto, composição farmacêutica, e, uso de um composto
BRPI0907562A2 (pt) composto, composição farmacêutica, e, uso de um composto
BRPI0921375A2 (pt) composto, composição farmacêutica, e, uso de um composto
BRPI0715712A2 (pt) Composição farmacêutica
BRPI0815190A2 (pt) Composto derivado de piridina, composição farmacêutica que o compreende e uso do mesmo
BRPI0719393A2 (pt) Composição farmacêutica
BRPI0917579A2 (pt) composto, composição farmacêutica, métodos, e, uso de um composto
BRPI0716327A2 (pt) Composto de fenilpropionamida e uso
BRPI0921879A2 (pt) composto, composição farmacêutica , e, uso de um composto
BRPI0716698A2 (pt) Composto, composição farmacêutica e uso de um composto
BRPI0812942A2 (pt) Composto, composição farmacêutica e uso de um composto
BRPI0810019A2 (pt) Composto, composição farmacêutica, e, uso de um composto
BRPI0906253A2 (pt) Composição de dentifrício, e, uso de uma composição
HRP20141261T1 (xx) Spojevi tioninija i njihove uporabe
BRPI0720234A2 (pt) Composição farmacêutica
BRPI0716445A2 (pt) composiÇço farmacÊutica

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 7A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2284 DE 14/10/2014.